Retinoic acid induces differentiation in neuroblastoma via ROR1 by modulating retinoic acid response elements

Illendula,Abhinav; Fultang,Norman; Peethambaran,Bela

doi:10.3892/or.2020.7681

Retinoic acid induces differentiation in neuroblastoma via ROR1 by modulating retinoic acid response elements

Authors:
- Abhinav Illendula
- Norman Fultang
- Bela Peethambaran
View Affiliations

Affiliations: Department of Biology, University of The Sciences in Philadelphia, Philadelphia, PA 19104, USA
Published online on: July 7, 2020 https://doi.org/10.3892/or.2020.7681
Pages: 1013-1024
Copyright: © Illendula et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neuroblastoma is the most common inheritable, solid neoplasm in children found under the age of 7 and accounts for approximately 7% of childhood cancers. A common treatment that has been prescribed for over a decade is retinoid therapy [using all‑trans retinoic acid (RA)]. Treatment with this differentiating agent has been revealed to progress the cells from their stem‑cell state to a mature neuronal state gaining classical neuronal characteristics, including the suppression of proliferation. However, the molecular mechanism underlying the action of RA treatment remains to be elucidated. In the present study, a novel mechanism of RA‑induced differentiation via regulation of receptor tyrosine kinase‑like orphan receptor 1 (ROR1) is reported. ROR1 is overexpressed in neuroblastoma but significantly downregulated in mature differentiated neurons. Hence, it was hypothesized that RA may modulate ROR1 leading to differentiation and termination of cancerous properties. Immunoblotting revealed that following RA treatment, ROR1 levels initially increased then sharply decreased by 96 h. This was paired with synaptophysin, a mature neuron marker, sharply increasing concurrently, providing evidence of differentiation by 96 h. Investigation of the ROR1 pathway confirmed ROR1‑dependent downstream activation of the PI3K/AKT signaling axis, a growth pathway previously demonstrated to promote differentiation. Chromatin immunoprecipitation revealed an increase in RAR binding to the promoters of ROR1 and its endogenous ligand, Wnt5a. This research provided compelling evidence that RA is able to modulate the expression of ROR1 and Wnt5a to promote differentiation through the expression of synaptophysin. This data combined with the overarching data from the scientific community regarding proliferation and other proliferative factors in early‑stage neurons provides a more in‑depth model of the process of differentiation in neurons.

View Figures

View References

1	Mitchell WG, Davalos-Gonzalez Y, Brumm VL, Aller SK, Burger E, Turkel SB, Borchert MS, Hollar S and Padilla S: Opsoclonus-ataxia caused by childhood neuroblastoma: Developmental and neurologic sequelae. Pediatrics. 109:86–98. 2002.PubMed/NCBI
2	Yahya FS and Al-Shami HA: Posterior mediastinal neuroblastoma masked as flaccid paraparesis in a 3 year child. Neurosciences (Riyadh). 24:320–323. 2019. View Article : Google Scholar : PubMed/NCBI
3	Louis CU and Shohet JM: Neuroblastoma: Molecular pathogenesis and therapy. Annu Rev Med. 66:49–63. 2015. View Article : Google Scholar : PubMed/NCBI
4	Habib EE, El-Kashef AT and Fahmy ES: Management of neuroblastoma: A study of first-and second-line chemotherapy responses, a single institution experience. Oncol Rev. 6:e32012. View Article : Google Scholar : PubMed/NCBI
5	Mandal A: Neuroblastoma treatment. (online) News- Medical.net. Available at: https://www.news-medical.net/health/Neuroblastoma-Treatment.aspx. Feb 27–2019
6	Adamson PC, Matthay KK, O'Brien M, Reaman GH, Sato JK and Balis FM: A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: A pediatric oncology branch, NCI and children's oncology group study. Pediatr Blood Cancer. 49:661–665. 2007. View Article : Google Scholar : PubMed/NCBI
7	Reynolds CP, Matthay KK, Villablanca JG and Maurer BJ: Retinoid therapy of high-risk neuroblastoma. Cancer Lett. 197:185–192. 2003. View Article : Google Scholar : PubMed/NCBI
8	Shipley MM, Mangold CA and Szpara ML: Differentiation of the SH-SY5Y human neuroblastoma cell line. J Vis Exp. 17:531932016.
9	Canon E, Cosgaya JM, Scsucova S and Aranda A: Rapid effects of retinoic acid on CREB and ERK phosphorylation in neuronal cells. Mol Biol Cell. 15:5583–5592. 2004. View Article : Google Scholar : PubMed/NCBI
10	Allenby G, Bocquel MT, Saunders M, Kazmer S, Speck J, Rosenberger M, Lovey A, Kastner P, Grippo JF and Chambon P: Retinoic acid receptors and retinoid X receptors: Interactions with endogenous retinoic acids. Proc Natl Acad Sci USA. 90:30–34. 1993. View Article : Google Scholar : PubMed/NCBI
11	Nagai J, Yazawa T, Okudela K, Kigasawa H, Kitamura H and Osaka H: Retinoic acid induces neuroblastoma cell death by inhibiting proteasomal degradation of retinoic acid receptor alpha. Cancer Res. 64:7910–7917. 2004. View Article : Google Scholar : PubMed/NCBI
12	Petrova IM, Malessy MJ, Verhaagen J, Fradkin LG and Noordermeer JN: Wnt signaling through the Ror receptor in the nervous system. Mol Neurobiol. 49:303–315. 2014. View Article : Google Scholar : PubMed/NCBI
13	Rangel MC, Bertolette D, Castro NP, Klauzinska M, Cuttitta F and Salomon DS: Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer. Breast Cancer Res Treat. 156:211–226. 2016. View Article : Google Scholar : PubMed/NCBI
14	Fultang N, Illendula A, Chen B, Wu C, Jonnalagadda S, Baird N, Klase Z and Peethambaran B: Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity. PLoS One. 14:e02177892019. View Article : Google Scholar : PubMed/NCBI
15	Borcherding N, Kusner D, Liu GH and Zhang W: ROR1, an embryonic protein with an emerging role in cancer biology. Protein Cell. 5:496–502. 2014. View Article : Google Scholar : PubMed/NCBI
16	Blanc E, Roux GL, Benard J and Raguenez G: Low expression of Wnt-5a gene is associated with high-risk neuroblastoma. Oncogene. 24:1277–1283. 2005. View Article : Google Scholar : PubMed/NCBI
17	Bastien J, Plassat JL, Payrastre B and Rochette-Egly C: The phosphoinositide 3-kinase/Akt pathway is essential for the retinoic acid-induced differentiation of F9 cells. Oncogene. 25:2040–2047. 2006. View Article : Google Scholar : PubMed/NCBI
18	Akkuratov EE, Wu J, Sowa D, Shah ZA and Liu L: Ouabain-induced signaling and cell survival in SK-N-SH neuroblastoma cells differentiated by retinoic acid. CNS Neurol Disord Drug Targets. 14:1343–1349. 2015. View Article : Google Scholar : PubMed/NCBI
19	Hämmerle B, Yañez Y, Palanca S, Cañete A, Burks DJ, Castel V and Font de Mora J: Targeting neuroblastoma stem cells with retinoic acid and proteasome inhibitor. PLoS One. 8:e767612013. View Article : Google Scholar : PubMed/NCBI
20	Niewiarowska-Sendo A, Patrzalek K, Kozik A and Guevara-Lora I: The effect of differentiation agents on inflammatory and oxidative responses of the human neuroblastoma cell line SK-N-SH. Acta Biochim Pol. 62:435–443. 2015. View Article : Google Scholar : PubMed/NCBI
21	Gassmann M, Grenacher B, Rohde B and Vogel J: Quantifying Western blots: Pitfalls of densitometry. Electrophoresis. 30:1845–1855. 2009. View Article : Google Scholar : PubMed/NCBI
22	Tan HY and Ng TW: Accurate step wedge calibration for densitometry of electrophoresis gels. Opt Commun. 281:3013–3017. 2008. View Article : Google Scholar
23	Pemberton K, Mersman B and Xu F: Using ImageJ to assess neurite outgrowth in mammalian cell cultures: Research data quantification exercises in undergraduate neuroscience lab. J Undergrad Neurosci Educ. 16:A186–A194. 2008.
24	Clevers H: Wnt/beta-catenin signaling in development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Wang Y, Chakravarty P, Ranes M, Kelly G, Brooks PJ, Neilan E, Stewart A, Schiavo G and Svejstrup JQ: Dysregulation of gene expression as a cause of cockayne syndrome neurological disease. Proc Natl Acad Sci USA. 111:14454–14459. 2014. View Article : Google Scholar : PubMed/NCBI
27	Frumm SM, Fan ZP, Ross KN, Duvall JR, Gupta S, VerPlank L, Suh BC, Holson E, Wagner FF, Smith WB, et al: Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. Chem Biol. 20:713–725. 2013. View Article : Google Scholar : PubMed/NCBI
28	Almstedt E, Elgendy R, Hekmati N, Rosén E, Wärn C, Olsen TK, Dyberg C, Doroszko M, Larsson I, Sundström A, et al: Integrative discovery of treatments for high-risk neuroblastoma. Nat Commun. 11:712020. View Article : Google Scholar : PubMed/NCBI
29	Ye C, Ho DJ, Neri M, Yang C, Kulkarni T, Randhawa R, Henault M, Mostacci N, Farmer P, Renner S, et al: DRUG-seq for miniaturized high-throughput transcriptome profiling in drug discovery. Nat Commun. 9:43072018. View Article : Google Scholar : PubMed/NCBI
30	Koster J, Volckmann R, Zwijnenburg D, Molenaar P and Versteeg R: R2: Genomics analysis and visualization platform. Cancer Res. 24902019.
31	Tarsa L and Goda Y: Synaptophysin regulates activity-dependent synapse formation in cultured hippocampal neurons. Proc Natl Acad Sci USA. 99:1012–1016. 2002. View Article : Google Scholar : PubMed/NCBI
32	Rogers HA, Ward JH, Miller S, Lowe J, Coyle B and Grundy RG: The role of the WNT/ß-catenin pathway in central nervous system primitive neuroectodermal tumours (CNS PNETs). Br J Cancer. 108:2130–2141. 2013. View Article : Google Scholar : PubMed/NCBI
33	Kam RK, Deng Y, Chen Y and Zhao H: Retinoic acid synthesis and functions in early embryonic development. Cell Biosci. 2:112012. View Article : Google Scholar : PubMed/NCBI
34	Donovan M, Olofsson B, Gustafson AL, Dencker L and Eriksson U: The cellular retinoic acid binding proteins. J Steroid Biochem Mol Biol. 53:459–465. 1995. View Article : Google Scholar : PubMed/NCBI
35	Lindley D, Goranov B, Ponthan F and Redfern C: Abstract# 5280: The role of retinoic acid receptors in differentiation, gene expression and apoptosis of neuroblastoma. Cancer Res. 69 (9 Suppl):S52802009.
36	Kedishvili NY: Retinoic acid synthesis and degradation. Subcell Biochem. 81:127–161. 2016. View Article : Google Scholar : PubMed/NCBI
37	Peinemann F, van Dalen EC, Enk H and Berthold F: Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation. Cochrane Database Syst Rev. 8:CD0106852017.PubMed/NCBI
38	Chen MC, Hsu SL, Lin H and Yang TY: Retinoic acid and cancer treatment. Biomedicine (Taipei). 4:222014. View Article : Google Scholar : PubMed/NCBI
39	Bown N: Neuroblastoma tumour genetics: Clinical and biological aspects. J Clin Pathol. 54:897–910. 2001. View Article : Google Scholar : PubMed/NCBI
40	Boeva V, Louis-Brennetot C, Peltier A, Durand S, Pierre-Eugene C, Raynal V, Etchevers HC, Thomas S, Lermine A, Daudigeos-Dubus E, et al: Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nat Genet. 49:1408–1413. 2017. View Article : Google Scholar : PubMed/NCBI
41	Ross RA, Biedler JL and Spengler BA: A role for distinct cell types in determining malignancy in human neuroblastoma cell lines and tumors. Cancer Lett. 197:35–39. 2003. View Article : Google Scholar : PubMed/NCBI
42	Qiao J, Paul P, Lee S, Qiao L, Josifi E, Tiao JR and Chung DH: PI3K/AKT and ERK regulate retinoic acid-induced neuroblastoma cellular differentiation. Biochem Biophys Res Commun. 424:421–426. 2012. View Article : Google Scholar : PubMed/NCBI
43	Fultang N, Illendula A, Lin J, Pandey MK, Klase Z and Peethambaran B: ROR1 regulates chemoresistance in Breast Cancer via modulation of drug efflux pump ABCB1. Sci Rep. 10:18212020. View Article : Google Scholar : PubMed/NCBI
44	O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J, Liu Q, et al: Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov. 3:1378–1393. 2013. View Article : Google Scholar : PubMed/NCBI
45	Park H, Awasthi A, Ayello J, Chu Y, Riddell SR, Rosenblum J, Lee DA and Cairo MS: ROR1-specific chimeric antigen receptor (CAR) NK cell immunotherapy for high risk neuroblastomas and sarcomas. Biol Blood Marrow Transplant. 23:S136–S137. 2017. View Article : Google Scholar
46	Dave H, Butcher D, Anver M and Bollard CM: ROR1 and ROR2-novel targets for neuroblastoma. Pediatr Hematol Oncol. 36:352–364. 2019. View Article : Google Scholar : PubMed/NCBI